DNTH Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of --. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat CEL-SCI Corp.'s return on equity of -230.36%.

Dianthus Therapeutics, Inc. has a consensus price target of $63.63, signalling upside risk potential of 41.84%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 736.61%. Given that CEL-SCI Corp. has higher upside potential than Dianthus Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.554, which suggesting that the stock is 55.419% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are larger than CEL-SCI Corp. quarterly revenues of --. Dianthus Therapeutics, Inc.'s net income of -$36.8M is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 526.28x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of -15814.98%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Cytokinetics, Inc.'s return on equity of --.

Dianthus Therapeutics, Inc. has a consensus price target of $63.63, signalling upside risk potential of 41.84%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $88.22 which suggests that it could grow by 39.31%. Given that Dianthus Therapeutics, Inc. has higher upside potential than Cytokinetics, Inc., analysts believe Dianthus Therapeutics, Inc. is more attractive than Cytokinetics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.554, which suggesting that the stock is 55.419% more volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.718%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Cytokinetics, Inc. quarterly revenues of $1.9M. Dianthus Therapeutics, Inc.'s net income of -$36.8M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 526.28x versus 86.42x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Day One Biopharmaceuticals, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of -49.57%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Day One Biopharmaceuticals, Inc.'s return on equity of -30.98%.

Dianthus Therapeutics, Inc. has a consensus price target of $63.63, signalling upside risk potential of 41.84%. On the other hand Day One Biopharmaceuticals, Inc. has an analysts' consensus of $23.56 which suggests that it could grow by 122.43%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Dianthus Therapeutics, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.554, which suggesting that the stock is 55.419% more volatile than S&P 500. In comparison Day One Biopharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Day One Biopharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Day One Biopharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Day One Biopharmaceuticals, Inc. quarterly revenues of $39.8M. Dianthus Therapeutics, Inc.'s net income of -$36.8M is lower than Day One Biopharmaceuticals, Inc.'s net income of -$19.7M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Day One Biopharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 526.28x versus 8.13x for Day One Biopharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of -90.04%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19%.

Dianthus Therapeutics, Inc. has a consensus price target of $63.63, signalling upside risk potential of 41.84%. On the other hand Lexicon Pharmaceuticals, Inc. has an analysts' consensus of $2.92 which suggests that it could grow by 143.33%. Given that Lexicon Pharmaceuticals, Inc. has higher upside potential than Dianthus Therapeutics, Inc., analysts believe Lexicon Pharmaceuticals, Inc. is more attractive than Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.554, which suggesting that the stock is 55.419% more volatile than S&P 500. In comparison Lexicon Pharmaceuticals, Inc. has a beta of 0.713, suggesting its less volatile than the S&P 500 by 28.692%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Lexicon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Lexicon Pharmaceuticals, Inc. quarterly revenues of $14.2M. Dianthus Therapeutics, Inc.'s net income of -$36.8M is lower than Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Lexicon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 526.28x versus 6.14x for Lexicon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.